Dyslipidemia

Discussing how approval of bempedoic acid impacts the role of PCSK9 inhibitors for lowering LDL-C.

New findings show eligible men and minority group patients are less likely to receive a fill for the novel drug class.

An open-label extension of GLAGOV shows the monoclonal antibody plus statin therapy is not associated with any new safety concerns.

A special edition ACC House Call with Deepak Bhatt, MD, to discuss the results of a meta-analysis looking at ticagrelor and MALE from 2 clinical trials.

Executive Director of Interventional Cardiovascular Programs at Brigham and Women's discusses some research he took part in being presented at this year's conference.

The author of the first systematic evaluation of commissural alignment in TAVR shares his team's findings.

Data published in NEJM demonstrate the siRNA agent's ability to lower cholesterol in patients with multiple conditions.

About 1 in every 20 adult Americans now reguarly uses vaping and e-cigarette products.

Results of a meta-analysis of more than 2 dozen studies indicate DCB treatment may actually reduce mortality risk long-term.

New data from EPI Lifestyle Conference 2020 is shedding light on the impact of initiating estradiol therapy closer to the onset of menopause.

New data from Brigham and Women's Hospital suggests sleep irregularity could be a risk factor for cardiovascular disease.

Research from the University of Texas examines how serum folate levels above or below a certain level were linked to an increase in cardiovascular mortality.

The non-statin, fixed-dose combination therapy received approval less than one week after bempedoic acid received approval for treatment of HeFH.

The approval is the second non-statin LDL-C lowering therapy from Esperion to receive approval in the month of February.

The approval of bempedoic acid (Nexletol) marks the first oral, non-statin therapy approved by the FDA as a lipid-lowering agent in nearly 20 years.

Clinical trial data for the lipid-lowering non-statin agent indicates it can lower LDL-C by as much as 18% when combined with maximally tolerated statins.

Research from the Karolinska Institute indicates ESC/EAS 2019 dyslipidemia guidelines could create an unforeseen financial burden due to new eligibility for PSCK9 class.

New data on the use of polygenic risk scores for predicting certain forms of cardiovascular disease raise questions about the validity of genetic scores in real-world settings.

Analysis using data from the Nurses' Health Study is shedding new light on the interaction of TMAO and coronary heart disease risk.

A pilot study found consumption of cocoa and epicatechin were linked to improved six-minute walking time in PAD patients.

Data from the TAUSSIG study supports the long-term use of evolocumab for the treatment of both phenotypes of hypercholesterolemia.

A new study sheds light on the impact of statins and metformin use on risk of death in prostate cancer patients.

Investigators link waist circumference with an increased risk of depression for patients with arterial stiffness.

Leading experts on nutrition and diabetes are recommending that patients still continue to follow current nutritional recommendations by the American Diabetes Association and other healthcare and governmental organizations that recommend consuming a diet rich in fruits and vegetables, while limiting red and processed meats.

A new review in the Journal of the American College of Cardiology is highlighting the impact of marijuana use on heart health.

Analysis of more than 20,000 individuals found excess belly fat—measured by waist circumference—was linked to a significantly increased risk for suffering recurrent ASCVD events.

A 62-year-old male with history of coronary artery disease and prior coronary bypass surgery eight years ago presents to the emergency department after having two days of intermittent shortness of breath since starting cephalexin (Keflex) for a skin infection three days ago. He states the shortness of breath seems to get worse about an hour after taking cephalexin (Keflex). Can you diagnose this patient?

A new study has found habitual tea drinkers lowered their risk of atherosclerotic cardiovascular disease, coronary heart disease, and stroke compared to never or non-habitual tea drinkers.

The U.S. Food and Drug Administration has approved an omega-3 fatty acid treatment as an add-on treatment to statin therapy to reduce the risk of cardiovascular disease in adults with elevated triglyceride levels.

A recent study from the Mayo Clinic of Rochester, MN is suggested diabetes mellitus is an independent risk factor for the development of heart failure.